Skip to main content
. 2023 Jun;27(6):444–450. doi: 10.5005/jp-journals-10071-24481

Table 1.

Total number of patients in each of the two groups included in the study

Group code Group description No. of cases Percentage of cases
Group A CAZ-AVI based therapy 78 75.0
Group B Polymyxin B/E-based combination therapy 26 (23: polymyxin B, 3: polymyxin E) 25.0
Total 104 100.0